| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PD 153035 | CTRPv2 | pan-cancer | AAC | 0.17 | 8e-05 |
| mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | -0.13 | 9e-05 |
| mRNA | KX2-391 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0003 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | 0.13 | 0.0003 |
| mRNA | WZ-1-84 | GDSC1000 | pan-cancer | AAC | 0.19 | 0.0003 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0004 |
| mRNA | GSK269962A | GDSC1000 | pan-cancer | AAC | -0.13 | 0.0004 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0005 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.18 | 0.0006 |
| mRNA | GSK429286A | GDSC1000 | pan-cancer | AAC | -0.12 | 0.0007 |